PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 323.50
Bid: 325.00
Ask: 328.50
Change: -7.50 (-2.27%)
Spread: 3.50 (1.077%)
Open: 329.00
High: 332.00
Low: 320.00
Prev. Close: 331.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec

Wed, 04th Nov 2020 09:40

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

----------

FTSE 100

----------

BOFA RAISES LLOYDS BANKING TO 'NEUTRAL' (UNDERPERFORM) - PRICE TARGET 30 (26) PENCE

----------

MORGAN STANLEY RAISES PRUDENTIAL PRICE TARGET TO 1,537 (1,471) PENCE - 'OVERWEIGHT'

----------

LIBERUM RAISES LAND SECURITIES TO 'BUY' ('HOLD')

----------

JPMORGAN CUTS EVRAZ PRICE TARGET TO 510 (520) PENCE - 'NEUTRAL'

----------

INDEPENDENT RESEARCH RAISES GLENCORE TO 'BUY' ('HOLD') - TARGET 178 (180) PENCE

----------

GOLDMAN SACHS RAISES NATIONAL GRID PRICE TARGET TO 956 (949) PENCE - 'NEUTRAL'

----------

UBS CUTS DS SMITH PRICE TARGET TO 305 (318) PENCE - 'NEUTRAL'

----------

BERNSTEIN CUTS IAG PRICE TARGET TO 200 (270) PENCE - 'OUTPERFORM'

----------

UBS CUTS BT GROUP PRICE TARGET TO 106 (108) PENCE - 'NEUTRAL'

----------

CREDIT SUISSE CUTS AB FOODS PRICE TARGET TO 2,400 (2,430) PENCE - 'OUTPERFORM'

----------

JPMORGAN CUTS AB FOODS PRICE TARGET TO 2,250 (2,740) PENCE - 'OVERWEIGHT'

----------

GOLDMAN SACHS CUTS AB FOODS PRICE TARGET TO 2,050 (2,360) PENCE - 'NEUTRAL'

----------

FTSE 250

----------

JPMORGAN RAISES ROYAL MAIL TO 'OVERWEIGHT' ('NEUTRAL') - TARGET 374 (253) PENCE

----------

JPMORGAN RAISES BIG YELLOW GROUP TO 'OVERWEIGHT' ('UNDERWEIGHT') - TARGET 1,250 (840) PENCE

----------

RBC CUTS IWG PRICE TARGET TO 300 (325) PENCE - 'SECTOR PERFORM'

----------

BERENBERG RAISES COATS GROUP PRICE TARGET TO 70 (65) PENCE - 'BUY'

----------

RBC RAISES COATS GROUP PRICE TARGET TO 85 (80) PENCE - 'OUTPERFORM'

----------

JPMORGAN RAISES WEIR GROUP PRICE TARGET TO 1,600 (1,450) PENCE - 'NEUTRAL'

----------

BERENBERG RAISES CHEMRING GROUP PRICE TARGET TO 320 (300) PENCE - 'BUY'

----------

JEFFERIES RAISES CREST NICHOLSON PRICE TARGET TO 280 (251) PENCE - 'HOLD'

----------

RBC CUTS BEAZLEY PRICE TARGET TO 415 (465) PENCE - 'OUTPERFORM'

----------

RBC RAISES HISCOX PRICE TARGET TO 875 (825) PENCE - 'SECTOR PERFORM'

----------

JEFFERIES RAISES OXFORD BIOMEDICA PRICE TARGET TO 860 (730) PENCE - 'HOLD'

----------

OTHER MAIN MARKET AND AIM

----------

JPMORGAN CUTS SENIOR PLC PRICE TARGET TO 55 (60) PENCE - 'NEUTRAL'

----------

RBC RAISES SPIRE HEALTHCARE TO 'OUTPERFORM' ('SECTOR PERFORM') TARGET 169 (115) PENCE

----------

LIBERUM RAISES GEM DIAMONDS TO 'BUY' ('HOLD') - TARGET 60 (30) PENCE

----------

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
28 Jan 2022 16:19

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

Read more
28 Jan 2022 12:13

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

Read more
28 Jan 2022 10:27

Oxford BioMedica to acquire 80% ownership of new US virus business

Oxford BioMedica to acquire 80% ownership of new US virus business

Read more
28 Jan 2022 09:56

Oxford Biomedica creates venture with Homology, launches £80m fundraise

(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.

Read more
17 Jan 2022 09:32

Oxford Biomedica starts search for new CEO as Dawson steps down

Oxford Biomedica starts search for new CEO as Dawson steps down

Read more
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
15 Dec 2021 09:33

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.